Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)

  • Technology appraisal
  • TA941
  • Published: 

The topic routing was discussed at the Topic Selection Oversight Panel (TSOP) in January 2023. The panel concluded that the topic was suitable for a Technology Appraisal.  Please see project documents for further details.

This page was last updated: